Minimising the long-term adverse effects of childhood leukaemia therapy

Drug Safety

Volumn 25, Issue 15, 2002, Pages 1057-1077

  Langebrake, Claudia ^a   Reinhardt, Dirk ^a   Ritter, Jörg ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ASPARAGINASE; ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; FLUDARABINE; GLUCOCORTICOID; IDARUBICIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTECTIVE AGENT; RAZOXANE; RETINOIC ACID DERIVATIVE; TIOGUANINE; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ARTERY OCCLUSION; AVASCULAR NECROSIS; BLADDER DISEASE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE NECROSIS; BONE PAIN; BRAIN HEMORRHAGE; BRAIN PSEUDOTUMOR; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GLOMERULONEPHRITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG DESIGN; DRUG FORMULATION; EDEMA; ELECTROLYTE DISTURBANCE; FANCONI RENOTUBULAR SYNDROME; FAT EMBOLISM; FEVER; GENITAL SYSTEM DISEASE; HEADACHE; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOALBUMINEMIA; HYPOINSULINEMIA; HYPOLIPOPROTEINEMIA; IMMUNOPATHOLOGY; INFERTILITY; INTRAHEPATIC CHOLESTASIS; LETHARGY; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG EDEMA; LUNG TOXICITY; MALAISE; METASTASIS; MINIMAL RESIDUAL DISEASE; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RETINOL INTOXICATION; REVIEW; RISK ASSESSMENT; SENSORY DYSFUNCTION; SKIN MANIFESTATION; SOMNOLENCE; TACHYCARDIA; THROMBOSIS; VEIN OCCLUSION; VOMITING;

ALKYLATING AGENTS; ANTHRACYCLINES; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; CARDIOVASCULAR DISEASES; CHILD; CLINICAL TRIALS; GLUCOCORTICOIDS; GONADAL DISORDERS; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; OSTEONECROSIS; PODOPHYLLOTOXIN; POLYETHYLENE GLYCOLS; TRETINOIN; VINCA ALKALOIDS;

EID: 0036905610     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225150-00002     Document Type: Review

References (172)

1. Kaatsch P, Kaletsch U. German childhood cancer registry: Annual report 1997 (Jahresbericht 1997 des Deutschen Kinder-krebsregisters). Mainz: Institut für Medizinische Statistik und Dokumentation, 1999
2. Ritter J. Acute myeloid leukaemias. Eur J Cancer 1998; 34 (6): 862-72
3. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001; 15 (3): 348-54
4. Ritter J, Creutzig U, Schellong G. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group. Leukemia 1992; 6 Suppl. 2: 59-62
5. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000; 14 (12): 2205-22
6. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988; 80 (8): 556-66
7. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002; 99 (1): 245-51
8. Ho PT, Zimmerman K, Wexler LH, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76 (12): 2557-64
9. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG late effects group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000; 82 (10): 1636-45
10. Shusterman S, Meadows AT. Long term survivors of childhood leukemia. Curr Opin Hematol 2000; 7 (4): 217-22
11. Schrader M, Heicappell R, Muller M, et al. Impact of chemotherapy on male fertility. Onkologie 2001; 24 (4): 326-30
12. Relander T, Cavallin-Stahl E, Garwicz S, et al. Gonadal and sexual function in men treated for childhood cancer. Med Pediatr Oncol 2000; 35 (1): 52-63
13. Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9 (7): 1215-23
14. Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986; 68 (5): 1114-8
15. von Bernuth G, Adam D, Hofstetter R, et al. Cyclophosphamide cardiotoxicity. Eur J Pediatr 1980; 134 (1): 87-90
16. Trigg ME, Finlay JL, Bozdech M, et al. Fatal cardiac toxicity in bone marrow transplant patients receiving cytosine arabinoside, cyclophosphamide, and total body irradiation. Cancer 1987; 59 (1): 38-42
17. Baello EB, Ensberg ME, Ferguson DW, et al. Effect of high-dose cyclophosphamide and total-body irradiation on left ventricular function in adult patients with leukemia undergoing allogeneic bone marrow transplantation. Cancer Treat Rep 1986; 70 (10): 1187-93
18. Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; 11 (6): 1039-45
19. Linassier C, Barin C, Calais G, et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000; 11 (10): 1289-94
20. Dunst J, Ahrens S, Paulussen M, et al. Second malignancies after treatment for Ewing's sarcoma: A report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998; 42 (2): 379-84
21. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998; 16 (9): 3016-20
22. Liu FT, Kelsey SM, Newland AC, et al. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells. Br J Haematol 2002; 117 (2): 333-42
23. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277 (13): 10883-92
24. Xu MF, Tang PL, Qian ZM, et al. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001; 68 (8): 889-901
25. De Atley SM, Aksenov MY, Aksenova MV, et al. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 1999; 134 (1): 51-62
26. Thompson JA, Hess ML. The oxygen free radical system: A fundamental mechanism in the production of myocardial necrosis. Prog Cardiovasc Dis 1986; 28 (6): 449-62
27. Iarussi D, Indolfi P, Galderisi M, et al. Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 2000; 25 (7): 676-88
28. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91 (5): 710-7
29. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982; 9 (1): 23-33
30. Lipshultz SE, Colan SD. Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324 (12): 808-15
31. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266 (12): 1672-7
32. Leahey AM, Teunissen H, Friedman DL, et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999; 32 (3): 163-9
33. Silber JH, Jakacki RI, Larsen RL, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21 (7): 477-9
34. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332 (26): 1738-43
35. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25 (4 Suppl. 10): 72-85
36. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol 2001; 19 (10): 2705-13
37. Dunn CJ, Goa KL. Mitoxantrone: A review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996; 9 (2): 122-47
38. Gantchev TG, Hunting DJ. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Biochem Biophys Res Commun 1997; 237 (1): 24-7
39. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-retated leukemia: Identification of a new subset of secondary leukemia. Cancer 1991; 68 (3): 600-4
40. Kitazawa J, Ito E, Arai K, et al. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 2001; 37 (2): 153-4
41. Haupt R, Fears TR. Heise A. et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations. Int J Cancer 1997; 71 (1): 9-3
42. Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16 (10): 3386-91
43. Stine KC, Saylors RL, Sawyer JR, et al. Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol 1997; 15 (4): 1583-6
44. Katato K, Flaherty L, Varterasian M. Secondary acute myelogenous leukemia following treatment with oral etoposide. Am J Hematol 1996; 53 (1): 54-5
45. Kollmannsberger C, Hartmann JT, Kanz L, et al. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998; 124 (3-4): 207-14
46. Meister B, Gassner I, Streif W, et al. Methotrexate osteopathy in infants with tumors of the central nervous system. Med Pediatr Oncol 1994; 23 (6): 493-6
47. Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. Med Pediatr Oncol 1996; 26 (2): 85-9
48. Ross SR, McTavish D, Faulds D. Fludarabine: A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993; 45 (5): 737-59
49. Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000; 22 (3): 206-13
50. Pieters R, van Brenk AI, Veerman AJ, et al. Bone marrow magnetic resonance studies in childhood leukemia: Evaluation of osteonecrosis. Cancer 1987; 60 (12): 2994-3000
51. Murphy RG, Greenberg ML. Osteonecrosis in pediatric patients with acute lymphoblastic leukemia. Cancer 1990; 65 (8): 1717-21
52. Harper PG, Trask C, Souhami RL. Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. BMJ (Clin Res Ed) 1984; 288 (6413): 267-8
53. Ishii E, Yoshida N, Miyazaki S. Avascular necrosis of bone in neuroblastoma treated with combination chemotherapy. Eur J Pediatr 1984; 143 (2): 152-3
54. Niebrugge DJ, Benjamin DR. Bone marrow necrosis preceding acute lymphoblastic leukemia in childhood. Cancer 1983; 52 (11): 2162-4
55. Strauss AJ, Su JT, Dalton VMK, et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 2001; 19 (12): 3066-72
56. Mattano Jr LA, Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the children's cancer group. J Clin Oncol 2000; 18 (18): 3262-72
57. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28 (2): 97-13
58. Ettinger LJ, Ettinger AG, Avramis VI, et al. Acute lymphoblastic leukemia: A guide to asparaginase and pegaspargase therapy. BioDrugs 1997; 7 (1): 30-9
59. Capizzi RL, Hotcenberg JS. Asparaginase. In: Holland JF, Frei E, Bast R, editors. Cancer Medicine. Philadelphia: Lea & Febiger, 1993: 796-805
60. Asselin BL. The three asparaginases: Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457: 621-9
61. Ettinger LJ, Kurtzberg J, Voute PA, et al. An open-label, multi-center study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995; 75 (5): 1176-81
62. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001; 80 (7): 417-22
63. Creutzig U, Ritter J, Zimmermann M, et al. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. J Clin Oncol 1993; 11 (2): 279-86
64. Nicholson HS, Byrne J. Fertility and pregnancy after treatment for cancer during childhood or adolescence. Cancer 1993; 71; 10: 3392-9
65. Liesner RJ, Leiper AD, Hann IM, et al. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994; 12 (5): 916-24
66. Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 1991; 9 (1): 145-51
67. Reinhardt D, Thiele C, Creutzig U. Neuropsychologische Folgen der prophytaktischen ZNS-Bestrahlung bei Kindern mit akuter myeloischer Leukaemie. Klin Padiatr 2002; 214 (1): 22-9
68. Butler RW, Hill JM, Steinherz PG, et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 1994; 12 (12): 2621-9
69. Paolucci G, Vecchi V, Favre C, et al. Treatment of childhood acute lymphoblastic leukemia: Long-term results of the AIEOP-ALL 87 study. Haematologica 2001; 86 (5): 478-84
70. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95 (11): 3310-22
71. Kamps WA, Bokkerink JP, Hahlen K, et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 1999; 94 (4): 1226-36
72. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97 (5): 1211-8
73. Donadieu J, Auclerc MF, Baruchet A, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables. FRALLE group. French Acute Lymphoblastic Leukaemia Study Group. Br J Haematol 1998; 102 (3): 729-39
74. Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia 2000; 14 (3): 356-63
75. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A Pediatric Oncology Group Study. Leukemia 2000; 14 (9): 1570-6
76. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998; 92 (2): 411-5
77. Schrappe M, Reiter A, Harbott J, et al. Improved risk-adapted treatment of childhood ALL with a new stratification system based on early response, genetics, age, and WBS: First interim analysis of trial ALL-BFM 95 [abstract]. Blood 2001; 98 (11): 718a
78. Amadori S, Testi AM, Arico M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993; 11 (6): 1046-54
79. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97 (1): 56-62
80. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101 (1): 130-40
81. Lie SO, Jonmundsson G, Mellander L, et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996; 94 (1): 82-8
82. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334 (22): 1428-34
83. Michel G, Baruchel A, Tabone MD, et al. Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia: A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther 1996; 38 (2): 169-76
84. AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103 (1): 100-9
85. Leung W, Hudson MM, Strickland DK, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000; 18 (18): 3273-9
86. Leung W, Hudson MM, Strickland DK, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000; 18 (18): 3273-9
87. van der Does-van den Berg A, de Vaan GA, van Weerden JF, et al. Late effects among long-term survivors of childhood acute leukemia in The Netherlands: A Dutch Childhood Leukemia Study Group Report. Pediatr Res 1995; 38 (5): 802-7
88. von der Weid N. Late effects in long-term survivors of ALL in childhood: Experiences from the SPOG late effects study. Swiss Med Wkly 2001; 131 (13-14): 180-7
89. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy. Blood 2000; 95 (9): 2770-5
90. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325 (19): 1330-6
91. Hortobagyi GN. Anthracyclines in the treatment of cancer: An overview. Drugs 1997; 54 Suppl. 4: 1-7
92. Forssen EA, Tokes ZA. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res 1983; 43 (2): 546-50
93. Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 1986; 77 (2): 459-69
94. Kanter PM, Bullard GA, Ginsberg RA, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 1993; 7 (1): 17-26
95. Rahman A, More N, Schein PS. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 1982; 42 (5): 1817-25
96. Sells RA, Owen RR, New RR, et al. Reduction in toxicity of doxorubicin by liposomal entrapment. Lancet 1987; II (8559): 624-5
97. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13 (7): 1777-85
98. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996; 4 (3): 129-40
99. Cortes J, Estey E, O'Brien S, et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001; 92 (1): 7-4
100. Eckardt JR, Campbell E, Burris HA, et al. A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol 1994; 17 (6): 498-501
101. Richardson DS, Kelsey SM, Johnson SA, et al. Early evaluation of liposomal daunorubicin (DaunoXome. Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 1997; 15 (3): 247-53
102. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9 (7): 711-6
103. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94 (1): 25-36
104. Fassas A, Buffels R, Anagnostopoulos A, et al. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: A phase I-II study. Br J Haematol 2002; 116 (2): 308-15
105. Whittaker JA, Al Ismail SA. Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia. BMJ (Clin Res Ed) 1984; 288 (6413): 283-4
106. Gupta M. Systolic time interval (STI) in adriamycin (ADM)-treated patients on digoxin or prednisone cardioprophylaxis. Proc Am Assoc Cancer Res 1976; 17: 269
107. Goa KL, Brogden RN. 1-Carnitine: A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987; 34 (1): 1-4
108. Cortes EP, Gupta M, Chou C, et al. Adriamycin cardiotoxicity: Early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 1978; 62 (6): 887-91
109. Dresdale AR, Barr LH, Bonow RO, et al. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol 1982; 5 (6): 657-63
110. Kolaric K, Bradamante V, Cervek J, et al. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology 1995; 52 (3): 251-5
111. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994; 28 (9): 1063-72
112. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319 (12): 745-52
113. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16 (1): 86-92
114. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14 (12): 3112-20
115. Links M, Lewis C. Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999; 57 (3): 293-308
116. Wiseman LR, Spencer CM. Dexrazoxane: A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998; 56 (3): 385-403
117. Basset RL, Sobol MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 1994; 12 (8): 1659-66
118. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxand for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15 (14): 1318-32
119. Goebel M. Oral idarubicin: An anthracycline derivative with unique properties. Ann Hematol 1993; 66 (1): 33-43
120. Tan CT, Hancock C, Steinherz P, et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res 1987; 47 (11): 2990-5
121. Cersosimo RJ, Hong WK. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4 (3): 425-39
122. Neri B, Cini-Neri G, Bandinelli M, et al. Doxorubicin and epirubicin cardiotoxicity: Experimental and clinical aspects. Int J Clin Pharmacol Ther Toxicol 1989; 27 (5): 217-21
123. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J ClinOncol 1990; 8 (11): 1806-10
124. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 1986; 46 (7): 3722-7
125. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7 (5): 560-71
126. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 1992; 19 (6): 670-86
127. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol 1999; 36 (4 Suppl. 6): 2-8
128. Sievers EL. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother Pharmacol 2000; 46: S18-22
129. Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97 (10): 3197-204
130. Sievers EL, Linenberger M. Mylotarg: Antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001; 13 (6): 522-57
131. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19 (13): 3244-54
132. Bross PF, Beitz J, Chen G. et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7 (6): 1490-6
133. Dillman RO, Beauregard JC, Jamieson M, et al. Toxicities associated with monoclonal antibody infusions in cancer patients. Mol Biother 1988; 1 (2): 81-5
134. Lester TJ, Johnson JW, Cuttner J. Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. Am J Med 1985; 79 (1): 43-8
135. Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27 (3): 347-61
136. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18 (4): 465-71
137. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92 (2): 406-13
138. Radford IR. Imatinib. Novartis. Curr Opin Investig Drugs 2002; 3 (3): 492-49
139. Kantarjian HM, Talpaz M. Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 2001; 28 (5 Suppl. 17): 9-8
140. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8 (5): 935-42
141. Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat 2001; 4 (1): 22-8
142. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61 (12): 1765-6
143. Elliott MA, Mesa RA, Tefferi A. Adverse events after imatinib mesylate therapy. N Engl J Med 2002; 346 (9): 712-3
144. Ottmann OG, Wassmann B, Hoelzer D. Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec). Med Klin 2002; 97 Suppl. 1: 16-21
145. Appelbaum FR, Matthews DC, Eary JF, et al. The use of radio-labeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54 (5): 829-33
146. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94 (4): 1237-47
147. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85 (4): 1122-31
148. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99 (6): 745-9
149. Lum BL, Svec JM, Torti FM. Doxorubicin: Alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharm 1985; 19 (4): 259-64
150. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96 (2): 133-9
151. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: A prospective randomized evaluation. Cancer 1990; 65 (4): 870-3
152. Berrak SG, Ewer MS, Jaffe N, et al. Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001; 8 (3): 611-4
153. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20 (6): 1677-82
154. Hunault-Berger M, Milpied N, Bernard M, et al. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: A randomized study. Leukemia 2001; 15 (6): 898-902
155. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996; 87 (12): 4979-89
156. Liu Yin JA, Wheatley K, Rees JK, et al. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113 (3): 713-26
157. Land VJ, Shuster JJ, Crist WM, et al. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1994; 12 (9): 1939-45
158. Loeb DM, Bowers DC, Civin CI, et al. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. Med Pediatr Oncol 2001; 37 (4): 365-71
159. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343 (8891): 196-200
160. Foroni L, Coyle LA, Papaioannou M, et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11 (10): 1732-41
161. Gruhn B, Hongeng S, Yi H, et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12 (5): 675-81
162. Panzer-Grumayer ER, Schneider M, Panzer S, et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95 (3): 790-4
163. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995; 9 (10): 1726-34
164. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352 (9142): 1731-8
165. van Dongen JJ, Szczepanski T, de Bruijn MA, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2 (2): 121-33
166. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 1995; 85 (6): 1416-34
167. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and
168. Benvenuto GM, La Vecchia L, Morandi P, et al. Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors. Ital Heart J 2000; 1 (11 Suppl.): 1457-63
169. Kumar S, Gupta RK, Bhake AS, et al. Cardiotoxic effects of high doses of cyclophosphamide in albino rats. Arch Int Pharmacodyn Ther 1992; 319: 58-65
170. Norgaard JM, Langkjer ST, Palshof T, et al. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001; 66 (3): 160-7
171. Brenner TL, Pui CH, Evan WE. Pharmacogenomics of childhood acute lymphoblastic leukemia. Curr Opin Mol Ther 2001; 3 (6): 567-78
172. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 2001; 1 (2): 99-108